Drug Profile
PF 3635659
Alternative Names: PF-03635659; PF-3635659Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 05 Oct 2010 Phase II development is ongoing
- 31 Jan 2010 Phase-II clinical trials in Chronic obstructive pulmonary disease in Germany (PO)
- 30 Sep 2008 Phase-I clinical trials in Chronic obstructive pulmonary disease in Belgium (unspecified route)